Presenting on Biotech in Europe and BioPharm America in September
(Thomson Reuters ONE) - (Oslo 11 September, 2009): Biotec Pharmacon has been invited topresent at Sachs Associates 9th Annual Biotech in Europe InvestorForum in Zürich on 14-15 September and on BioPharm America in SanFrancisco on 16-18 September.The presentations will be held by Sven Rohmann, VP BusinessDevelopment in Biotec Pharmacon. The presentations will be madeavailable on the company's web site www.biotec.no.Please also refer to:http://www.sachsforum.com/zurich09/index.htmlhttp://www.ebdgroup.com/bpa/For further information, please contact:CEO Lars Viksmoen, tel: +47 40620870VP Sven Rohmann, tel: +41 79 577 8895About Biotec Pharmacon:The biopharmaceutical company Biotec Pharmacon developspharmaceutical products for prevention and treatment of immunerelated diseases. The company has developed the bioactive substanceSBG (soluble beta glucan), which is in clinical phase III for twoindications; treatment of diabetic ulcers and prevention andtreatment of oral mucositis. The company's clinical developmentprogram also includes immune therapy of cancer, where combinationtreatments with SBG and monoclonal antibodies are being studied inclinical phase I/II. In addition, the company is involved in severalpreclinical studies with SBG. Biotec Pharmacon also produces andmarkets non-pharmaceutical health- and diagnostic products and owns100% of Immunocorp Consumer Health AS and the marine enzyme companyBiotec Marine Biochemicals AS.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 11.09.2009 - 08:30 Uhr
Sprache: Deutsch
News-ID 5708
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 253 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Presenting on Biotech in Europe and BioPharm America in September"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotec Pharmacon ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
